San Diego, CA, May 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces several new studies demonstrating comprehensive validation and clinical utility of its Breast Cancer Index genomic assay for early-stage, HR+ breast cancer that will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Conference.
- Breast Cancer Index and its ability to predict extended endocrine benefit from extended aromatase inhibitor therapy in the IDEAL (Investigation on the Duration of Extended Adjuvant Letrozole ) trial will be presented (Liefers et al), representing the largest validation to date with 908 HR+, early-stage breast cancer patients. It is also the first study to evaluate prediction of benefit from extended treatment with an aromatase inhibitor (AI) following initial treatment with an AI.
- Additional results from the Trans-aTTom (Adjuvant Tamoxifen to Offer More) study including 789 HR+ patients will be disclosed (Bartlett, et al) examining Breast Cancer Index predictive performance for extended endocrine benefit across HER2 subsets in HR+ patients treated with tamoxifen.
- Furthermore, results from an ongoing study in collaboration with Yale University (Foldi et al) evaluated the impact of Breast Cancer Index results on patient adherence to extended endocrine therapy.
Catherine Schnabel, Ph.D., Chief Scientific Officer, Biotheranostics, said, “We are pleased to continue to strengthen the clinical utility evidence for the Breast Cancer Index with new pivotal large-scale studies premiering at ASCO this year that further establish its distinct and important role in endocrine therapy decision-making.”
Don Hardison, Biotheranostics’ President and CEO adds, “Breast Cancer Index continues to demonstrate its ability to predict which hormone receptor positive patients are likely to benefit from additional anti-estrogen therapy vs those who will not. The convergence of our strong scientific evidence and our commercial efforts allows us to provide information that women and their providers deserve when making difficult joint decisions about prolonged treatment with anti-estrogen therapy. We are fortunate to offer the only commercially available biomarker that predicts benefit of extended endocrine therapy.”
About Breast Cancer Index®
Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early stage, HR+ breast cancer. This breakthrough test helps oncologists and patients navigate the difficult trade-off between taking steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to unnecessary treatment. Breast Cancer Index holds guidelines designation from the American Joint Committee on Cancer for cancer staging based on molecular profile; ASCO, NCCN, European Group on Tumor Markers (EGTM), and St. Gallen to inform the chemotherapy decision; and ASCO and EGTM to inform the extended endocrine treatment dilemma. It is the only validated, commercially available test that provides risk of overall and late distant recurrence and predicts the likelihood of benefit from extended endocrine therapy. For more information, visit www.breastcancerindex.com.
About Biotheranostics
Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California. Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients. Its suite of proprietary molecular diagnostic tests provides important information to physicians to tailor treatment to individual patients. The company's Breast Cancer Index® and CancerTYPE ID® tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Learn more at www.biotheranostics.com.